NEWS RELEASE

nDatalyze announces updates on Private Placement

Calgary, Alberta – March 21, 2022

For Immediate Release – nDatalyze Corp. ("**NDAT**" or the "**Corporation**") (CSE: NDAT)(OTC: NDATF) announces the Corporation has issued a total of 1,534,000 units ("**Units**"), for proceeds of $383,500, under its previously announced private placement ("**Offering**"). Each Unit consisted of one common share and one common share purchase warrant, with each warrant entitling the holder to acquire one common share AT $0.35 for 12 months from the date of issuance, subject to the accelerated expiry provision described in the Corporation's February 4, 2022 news release.

The Corporation expects to close additional tranches of the Offering shortly. All securities issued in connection with the Offering will be subject to a statutory hold period of four months plus a day from the date of issuance in accordance with applicable securities legislation in Canada.

The proceeds from the Offering will be used for general working capital. The Corporation may pay finders fees and finder warrants to eligible finders.

About nDatalyze Corp.:

nDatalyze Corp. generates technology-based, health-related solutions. The YMI division is developing a machine-learning based, online consumer mental health application and the MLdelic division is focusing on applying machine-learning to assist in the prediction of potential benefits associated with the use of entheogenic compounds within the mental health sector. Both YMI and MLdelic are based on the Corporation's proprietary Reference Database consisting of >1200 biometric records complete with "same-time-of-day" EEG data. With installations worldwide, its Medxtractor division manufactures and sells small-scale bio-extractors that are used to extract compounds from a variety of botanical biomasses. While the Medxtractor division is currently generating cash flow, both YMI and MLdelic are in development and accordingly the Corporation cannot accurately predict if or when these applications will become cash flow generators.

FOR FURTHER INFORMATION, PLEASE CONTACT:

nDatalyze Corp.
James Durward, President and CEO
Telephone: (403) 689-3901
Email: jimd@ndatalyze.com Website: www.ndatalyze.com

About nDatalyze Corp.:

nDatalyze Corp. generates technology-based, health-related solutions. The YMI division is developing a machine-learning based, online consumer mental health application and the MLdelic division is focusing on applying machine-learning to assist in the prediction of potential benefits associated with the use of entheogenic compounds within the mental health sector. Both YMI and MLdelic are based on the Corporation's proprietary Reference Database consisting of >1200 biometric records complete with "same-time-of-day" EEG data. With installations worldwide, its Medxtractor division manufactures and sells small-scale bio-extractors that are used to extract compounds from a variety of botanical biomasses. While the Medxtractor division is currently generating cash flow, both YMI and MLdelic are in development and accordingly the Corporation cannot accurately predict if or when these applications will become cash flow generators.

FOR FURTHER INFORMATION, PLEASE CONTACT:

nDatalyze Corp.
James Durward, President and CEO
Telephone: (403) 689-3901
Email: jimd@ndatalyze.com Website: www.ndatalyze.com